1. |
Chemotherapy in head and neck cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1320,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
Drug safety issues in 2001 |
|
Inpharma Weekly,
Volume &NA;,
Issue 1320,
2002,
Page 3-6
Sam Masters,
Preview
|
|
摘要:
In 2001, there were a considerable number of market withdrawals, the most high profile of which was the worldwide withdrawal of cerivastatin. Additionally, there were many significant labelling changes throughout the year resulting from safety concerns. In particular, bupropion received a lot of media attention and was subject to a number of safety updates throughout the year.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1320,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
β-Lactams linked to pneumococcal carriage in paediatric individuals |
|
Inpharma Weekly,
Volume &NA;,
Issue 1320,
2002,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Routine hepatitis A vaccination controls disease incidence |
|
Inpharma Weekly,
Volume &NA;,
Issue 1320,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
Cancer news from the 4th Annual ISPOR MeetingCannes, France November 2001 |
|
Inpharma Weekly,
Volume &NA;,
Issue 1320,
2002,
Page 9-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
Sirolimus-eluting stent: positive 6-month results |
|
Inpharma Weekly,
Volume &NA;,
Issue 1320,
2002,
Page 10-10
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1320,
2002,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1320,
2002,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
Capecitabine combination therapy promising in solid tumours |
|
Inpharma Weekly,
Volume &NA;,
Issue 1320,
2002,
Page 13-14
Sushma Soni,
Preview
|
|
摘要:
Monotherapy with the orally-administered fluoropyrimidine capecitabine ['Xeloda'] has shown efficacy in the treatment of solid tumours such as breast cancer and colorectal cancer. Now, studies presented at ECCO 11 - the European Cancer Conference [Lisbon, Portugal; October 2001], have shown that capecitabine can also produce very promising results when administered in combination with other antineoplastics, with manageable toxicity. Capecitabine has shown superior tolerability to IV bolus fluorouracil [5-FU], as capecitabine exploits the higher thymidine phosphorylase activity in malignant tissue to be predominantly converted to fluorouracil at the tumour site.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|